Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004216 · ClinicalTrials.gov registry record · Phase 1
VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy
A Phase 1 study, sponsored by Vion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004216: Completed Phase 1 study, sponsored by Vion Pharmaceuticals.
NCT00004216 is a Phase 1 study that has completed, run by Vion Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004216, a Phase 1 study, has completed, sponsored by Vion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Biological therapies such as VNP20009 use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of VNP20009 in treating patients who have advanced or metastatic solid tumors that have not responded to previous therapy.
Interventions
- DRUG trimethoprim-sulfamethoxazole
- DRUG ciprofloxacin
- BIOLOGICAL salmonella VNP20009
- DRUG cefixime
- DRUG ceftriaxone sodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-08 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
What the finished NCT00004216 record still lists
NCT00004216 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which trimethoprim-sulfamethoxazole is the first listed.
NCT00004216 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004216 about?
NCT00004216 is a clinical study titled "VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy". RATIONALE: Biological therapies such as VNP20009 use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of VNP20009 in treating patients who have advanced or metastatic solid tumors that have not responded to previous ...
What is the current status of trial NCT00004216?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-08. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00004216?
The interventions under investigation include: trimethoprim-sulfamethoxazole (DRUG), ciprofloxacin (DRUG), salmonella VNP20009 (BIOLOGICAL), cefixime (DRUG), ceftriaxone sodium (DRUG).
Who is sponsoring clinical trial NCT00004216?
This trial is sponsored by Vion Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia